Hee Chul Park
성균관대학교 의과대학 · 의학
Hee Chul Park 교수의 연구실은 난이도 높은 암 치료 도전 과제인 저산소성 환경에서의 방사선 저항성 극복을 핵심 목표로 삼고 있습니다. 특히 난소암, 간세포암 등에서의 방사선 치료 효능을 높이기 위해 나노입자 기반의 산소 생성제제(예: 히알루론산-망간다이옥사이드 나노입자)와 천연물 유래 물질(예: 푸코이단)을 융합한 신개념 약물 전달 시스템을 개발하고 있습니다. 또한, 면역검사제제(nivolumab)와의 조합요법을 통한 종양 미세환경 조절 및 임상적 유효성 검증에도 집중하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Tumor hypoxia is a major mechanism of resistance to radiation therapy (RT), which is associated with poor prognosis in affected cancer patients. Various approaches to treat hypoxic and radioresistant cancers, including pancreatic cancer, have shown limited success. Fucoidan, a polysaccharide from brown seaweed, has antitumor and antiangiogenesis activities. Here, we discuss the development of fucoidan-coated manganese dioxide nanoparticles (Fuco-MnO₂-NPs) and testing of the therapeutic potential
A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based
Previous and/or concurrent application of RT in the course of nivolumab treatment was related with longer PFS and OS in advanced HCC patients. Nonetheless, further clinical studies are warranted to confirm our findings.
